{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:04:38Z","timestamp":1783184678533,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clml.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:29:11Z","timestamp":1695130151000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies"],"prefix":"10.1016","volume":"24","author":[{"given":"Muhammed Talha","family":"Bilgihan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Nur","family":"Eryigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-8531","authenticated-orcid":false,"given":"Rafiye","family":"Ciftciler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2023.09.002_bib0001","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.09.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.clml.2023.09.002_bib0003","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5483\/BMBRep.2022.55.2.183","article-title":"Emerging role of bystander T cell activation in autoimmune diseases","volume":"55","author":"Shim","year":"2022","journal-title":"BMB Rep"},{"key":"10.1016\/j.clml.2023.09.002_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.09.002_bib0005","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.4049\/jimmunol.157.11.4762","article-title":"Regulation of surface and intracellular expression of CTLA4 on mouse T cells","volume":"157","author":"Alegre","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2023.09.002_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982026","article-title":"Harnessing the immune system by targeting immune checkpoints: providing new hope for oncotherapy","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.clml.2023.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.clml.2023.09.002_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33309\/2639-8354.010103","article-title":"Approved programmed cell death-1 inhibitors in Hodgkin Lymphoma: the first breakthrough of immune checkpoint inhibitors in hematologic malignancies","volume":"1","author":"Gong","year":"2018","journal-title":"Clin Res Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14737140.2021.1918548","article-title":"Immune checkpoint inhibition in classical Hodgkin lymphoma","volume":"21","author":"Pezeshki","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"23","key":"10.1016\/j.clml.2023.09.002_bib0012","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.09.002_bib0013","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.002_bib0015","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1182\/blood-2022-164808","article-title":"Combination therapy of nivolumab in first line and relapsed\/refractory classic Hodgkin's lymphoma: a systematic review and meta-analysis of clinical trials","volume":"140","author":"Parmar","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.09.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2181749","article-title":"Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies","volume":"28","author":"Sun","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2023.09.002_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.HS9.0000890968.53519.f4","article-title":"T100: long term follow-up of a phase I study combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in patients with relapsed\/refractory Hodgkin Lymphoma: a trial of the ECOG-ACRIN Research Group (E4412: Arms AI)","volume":"6","author":"Diefenbach","year":"2022","journal-title":"Hemasphere"},{"issue":"13","key":"10.1016\/j.clml.2023.09.002_bib0018","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2023.09.002_bib0019","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.clml.2023.09.002_bib0020","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.3390\/jcm12072535","article-title":"Vinorelbine and intermittent cyclophosphamide sensitize an aggressive myc-driven B-cell lymphoma to Anti-PD-1 by an immunological memory effective against tumor re-challenge","volume":"12","author":"Orecchioni","year":"2023","journal-title":"J Clin Med"},{"issue":"50","key":"10.1016\/j.clml.2023.09.002_bib0021","doi-asserted-by":"crossref","first-page":"e32333","DOI":"10.1097\/MD.0000000000032333","article-title":"Efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating non-hodgkin lymphoma: a systematic review and meta-analysis of clinical trials","volume":"101","author":"Guan","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.clml.2023.09.002_bib0022","first-page":"164","article-title":"The role of immune checkpoint blockade in acute myeloid leukemia","volume":"2","author":"Silva","year":"2022","journal-title":"Onco (Basel)"},{"key":"10.1016\/j.clml.2023.09.002_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2023.09.002_bib0024","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.clml.2023.09.002_bib0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2023.09.002_bib0026","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.09.002_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-142824","article-title":"Azacitidine (AZA) with nivolumab (Nivo), and AZA with Nivo+ ipilimumab (Ipi) in relapsed\/refractory (R\/R) acute myeloid leukemia: clinical and immune biomarkers of response","volume":"136","author":"Naval Daver","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis","volume":"12","author":"G\u00f3mez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.09.002_bib0029","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1182\/blood-2021-153632","article-title":"A phase 2 multi-center, open label study of Isatuximab added to standard cybord induction and lenalidomide maintenance treatments in newly diagnosed, transplant eligible multiple myeloma","volume":"138","author":"Kotb","year":"2021","journal-title":"Blood"},{"issue":"47","key":"10.1016\/j.clml.2023.09.002_bib0030","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.002_bib0031","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1182\/blood-2022-170279","article-title":"Interim results of a phase 1\/2 study of Pembrolizumab combined with Blinatumomab in patients with relapsed\/refractory (r\/r) ALL","volume":"140","author":"Sandhu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.002_bib0032","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.09.002_bib0033","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: second-line drugs of choice","volume":"91","author":"Gambacorti-Passerini","year":"2016","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.09.002_bib0034","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819031000119235","article-title":"Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases","volume":"44","author":"Zaja","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2023.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.09.002_bib0036","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.09.002_bib0037","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.clml.2023.09.002_bib0038","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.09.002_bib0039","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2023.09.002_bib0041","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1080\/10428194.2021.1889536","article-title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","volume":"62","author":"Mart\u00ednez-L\u00f3pez","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2023.09.002_bib0042","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","article-title":"Myelodysplastic syndromes","volume":"8","author":"Li","year":"2022","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.clml.2023.09.002_bib0043","article-title":"The yin-yang of immunity: immune dysregulation in myelodysplastic syndrome with different risk stratification","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.clml.2023.09.002_bib0044","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2022.2034155","article-title":"Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study","volume":"63","author":"Garcia-Manero","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2023.09.002_bib0045","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2023.09.002_bib0046","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","article-title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","volume":"6","author":"Gerds","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.clml.2023.09.002_bib0047","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.09.002_bib0048","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-142003","article-title":"A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)","volume":"136","author":"Morita","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.09.002_bib0049","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"issue":"429","key":"10.1016\/j.clml.2023.09.002_bib0050","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.clml.2023.09.002_bib0051","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3390\/ijms23105837","article-title":"PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in ph (-) myeloproliferative neoplasm: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.clml.2023.09.002_bib0052","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","article-title":"PD-1 inhibition in advanced myeloproliferative neoplasms","volume":"5","author":"Hobbs","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.09.002_bib0053","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1007\/s00277-021-04618-5","article-title":"Phase II study of single-agent nivolumab in patients with myelofibrosis","volume":"100","author":"Abou Dalle","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.09.002_bib0054","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options","volume":"30","author":"Le Calvez","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.clml.2023.09.002_bib0055","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/ijms24065730","article-title":"Inappropriate expression of PD-1 and CTLA-4 checkpoints in Myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors","volume":"24","author":"Kulikowska de Na\u0142\u0119cz","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clml.2023.09.002_bib0056","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2023.09.002_bib0057","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.09.002_bib0058","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jtct.2020.12.026","article-title":"Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation","volume":"27","author":"Skarbnik","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.clml.2023.09.002_bib0059","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.clml.2023.09.002_bib0060","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2023.09.002_bib0061","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.09.002_bib0062","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood-2019-124339","article-title":"Efficacy and safety of nivolumab combined with daratumumab with or without low-dose cyclophosphamide in relapsed\/refractory multiple myeloma; interim analysis of the phase 2 Nivo-Dara study","volume":"134","author":"Verkleij","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.09.002_bib0063","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/cancers13102452","article-title":"Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients","volume":"13","author":"Frerichs","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clml.2023.09.002_bib0064","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3906\/sag-1807-152","article-title":"The impact of JAK\/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases","volume":"49","author":"T\u00fcrk","year":"2019","journal-title":"Turk J Med Sci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023015495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:58Z","timestamp":1761871378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023015495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2152265023015495"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}